BridgeBio Pharma, Inc. (BBIO) Social Stream



BridgeBio Pharma, Inc. (BBIO): $10.70

0.10 (+0.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BridgeBio Pharma Inc (BBIO) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering BBIO.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-05 8 $88 $68 $79.625 $10.15 684.48%
2021-12-03 8 $88 $66 $79.375 $10.15 682.02%
2022-01-18 8 $86 $17 $41.125 $10.15 305.17%
2022-02-24 8 $86 $17 $40.875 $10.15 302.71%
2022-02-28 8 $86 $17 $40.375 $10.15 297.78%
2022-03-08 7 $80 $17 $32 $10.15 215.27%
2022-03-15 7 $80 $17 $31.857 $10.15 213.86%
2022-03-16 7 $80 $17 $31.571 $10.15 211.04%

The Trend in the Analyst Price Target


Over the past 14 months, BBIO's average price target has gone down $32.18.

BBIO reports an average of 128.57% for its upside potential over the past 50 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-03 4 91 75 84.22 59.36 41.88%
2021-06-13 10 91 71 81.63 63.93 27.69%
2021-08-14 10 91 66 80.88 50.12 61.37%
2021-09-18 9 91 66 80.40 52.12 54.26%
2021-09-19 9 91 66 80.40 52.12 54.26%

BBIO Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.14 6 1 0 0 0 7

The Trend in the Broker Recommendations


Over the past 120 days, BBIO's average broker recommendation rating worsened by 0.02.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, BridgeBio Pharma Inc's variance in analysts' estimates is lower than -658.52% of them.
  • BBIO has a higher upside potential (average analyst target price relative to current price) than 827.57% of all US stocks.
  • In terms of how BridgeBio Pharma Inc fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is greater than 594.06% of that group.
  • In terms of how BridgeBio Pharma Inc fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 570.23% of that group.

In the Pharmaceutical Products industry, AXSM, AVIR, and AUPH are the three stocks most similar to BridgeBio Pharma Inc regarding the price target and analyst recommendation information presented here.

Is BBIO a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4894 seconds.